Toward the harmonization of immune monitoring in clinical trials: Quo vadis?

Cancer Immunology, Immunotherapy

Volumn 57, Issue 3, 2008, Pages 285-288

  Britten, C M ^a   Janetzki, S ^b   Van Der Burg, S H ^a   Gouttefangeas, C ^c   Hoos, A ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ZellNet Consulting Inc   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CD8 ANTIGEN; TUMOR ANTIGEN;

ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICAL RESEARCH; MONITORING; NOTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; VALIDATION PROCESS;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MONITORING, IMMUNOLOGIC; NEOPLASMS; PREDICTIVE VALUE OF TESTS;

EID: 37349107479     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0379-z     Document Type: Note

References (12)

1. Romero P, Cerottini JC, Speiser DE (2004) Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother 53:249
2. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909
3. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G (2007) Cancer vaccine clinical trial working groupA clinical development paradigm for cancer vaccines and related biologics. J Immunother 30:1
4. Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D'Souza MP (2005) Elispot collaborative study group results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses 21:68
5. Janetzki S, Cox JH, Oden N, Ferrari G (2005) Standardization and validation issues of the ELISPOT assay. Methods Mol Biol 302:51
6. Hanekom WA, Dockrell HM, Ottenhoff THM, Doherty TM, Fletcher H, McShane H, Weichold FF, Hoft DF, Parida SK, Fruth UJ (2007) Immunological outcomes of novel TB vaccine trials: WHO panel recommendations (submitted)
7. Speiser DE, Pittet MJ, Guillaume P, Lubenow N, Hoffman E, Cerottini JC, Romero P (2004) Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J Immunother 27:298
8. Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A (2006) Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res 12:107
9. + T lymphocytes by structural and functional assays. Cancer Immunol Immunother. doi:10.1007/s00262-007-0378-0
10. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WA, Hoos A, for the Elispot proficiency panel of the CVC immune assay working group (2007) Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) Cancer Immunol Immunother. doi:10.1007/s00262-007-0380-6
11. Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerottini JC, Wölfel T, Eggermont AM, Keilholz U (2000) Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods 244:81
12. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97